Compare Estee Lauder Companies Inc (EL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Recursion Pharmaceuticals Inc — how do they compare? Estee Lauder Companies Inc trades at $93.84 (market cap $34.22B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B). The key difference: Estee Lauder Companies Inc is far larger — about 14.8× Recursion Pharmaceuticals Inc's market cap, and Estee Lauder Companies Inc pays a 1.48% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EL | RXRX | |
|---|---|---|
Market Cap | $34.22B | $2.31B |
Volume | 2,303,792 | 40,478,768 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $6.79 |
52-Week Low | $67.23 | $2.84 |
Typical Hold Time | 122 Days | 22 Days |
Enterprise Value | $39.97B | $1.83B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $94.32, up 1.03% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported a net loss of $1.13 billion in 2025 despite a high gross margin of 75.5%, while 2026 forecasts show a return to profitability. Analysts maintain a consensus buy rating with a $103 price target, supported by strategic partnerships in AI and leadership changes aimed at driving growth.
The stock's outlook is cautiously optimistic, with earnings recovery and digital initiatives offering upside, but high debt levels and margin pressures pose risks. Investor sentiment is mixed amid volatile cash flows and competitive headwinds in the beauty sector.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
